CA
CPRX

CoreCap Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

CoreCap Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44K Sell
1,401
-399
-22% -$11.8K ﹤0.01% 1459
2026
Q1 		$44.6K Sell
1,800
-450
-20% -$10.7K ﹤0.01% 1359
2025
Q4 		$52.5K Sell
2,250
-125
-5% -$2.78K ﹤0.01% 1317
2025
Q3 		$46.8K Sell
2,375
-25,006
-91% -$514K ﹤0.01% 1351
2025
Q2 		$594K Sell
27,381
-6,861
-20% -$162K 0.02% 472
2025
Q1 		$830K Sell
34,242
-1,638
-5% -$36.9K 0.04% 371
2024
Q4 		$749K Buy
35,880
+35,480
+8,870% +$762K 0.03% 382
2024
Q3 		$7.95K Hold
400
– – ﹤0.01% 1858
2024
Q2 		$6.2K Sell
400
-300
-43% -$4.67K ﹤0.01% 1138
2024
Q1 		$11.2K Buy
+700
New +$10.5K ﹤0.01% 1707
2023
Q3 		– Sell
-14,913
Closed -$200K – 564
2023
Q2 		$200K Buy
+14,913
New +$215K 0.01% 536
2022
Q4 		$160K Buy
+8,612
New +$133K 0.01% 588
2022
Q1 		– Sell
-6,000
Closed -$41K – 850
2021
Q4 		$41K Buy
+6,000
New +$39.5K ﹤0.01% 1064

Other funds holding CPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
OLA
Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CoreCap Advisors's CPRX Position: Q2 2026 in Review

CoreCap Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 22% in Q2 2026, selling an estimated $11.8K and leaving 1,401 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #1459.

CoreCap Advisors first reported a position in CPRX in Q4 2021 and has held it in 13 quarters since. The position peaked at $830K in Q1 2025. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • CoreCap Advisors held 1,401 shares of Catalyst Pharmaceutical worth $44K as of Q2 2026.
  • CoreCap Advisors sold 399 Catalyst Pharmaceutical shares in Q2 2026, an estimated $11.8K.
  • Catalyst Pharmaceutical made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #1459 holding.
  • CoreCap Advisors first reported a position in Catalyst Pharmaceutical in Q4 2021 and has held it in 13 quarters since.
  • CoreCap Advisors's Catalyst Pharmaceutical position peaked at $830K in Q1 2025.
  • 36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.